Announcements Trials
Browse Landscape

Phase

Phase 2 48Phase 1/2 7Phase NA 5Phase 1 5Phase 4 2Phase 3 1

Status

Completed 57Terminated 20Active not recruiting 20Recruiting 17Withdrawn 7Unknown 5Suspended 3Not yet recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1Locally Advanced Rectal Carcinoma 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Cyclophosphamide 51fludarabine 38Injections 32Gemcitabine 25Paclitaxel 24Cisplatin 22Radiotherapy 19toripalimab 18pembrolizumab 18Carboplatin 17Capecitabine 17Fluorouracil 15Oxaliplatin 14Nivolumab 14Docetaxel 12camrelizumab 11apatinib 11Temozolomide 11Immunotherapy, Adoptive 11Cetuximab 11Bevacizumab 10Irinotecan 9Drug Therapy 9sintilimab 8Etoposide 8aldesleukin 7Taxes 7Rituximab 7Radiosurgery 7Peripheral Blood Stem Cell Transplantation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Unknown × durvalumab × Clear all
NCT06304597 2024-03-12

PREDICT

University Medical Center Groningen

Phase 1 Unknown
18 enrolled
Gastrointestinal

Locally Advanced Rectal Carcinoma

NCT03799744 2022-03-28

Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma

Institut Català d'Oncologia

Phase 1 Unknown
20 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT05157542 2021-12-15

Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC

Sichuan Cancer Hospital and Research Institute

Phase 1 Unknown
9 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05008861 2021-08-17

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Shanghai Zhongshan Hospital

Phase 1 Unknown
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03283943 2018-07-11

PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.

British Columbia Cancer Agency

Phase 1 Unknown
22 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡